Asthma/Lower Airway Diseases

Top Story

FDA approves Fasenra for eosinophilic asthma maintenance therapy

November 15, 2017

The FDA has approved Fasenra for additional maintenance treatment of severe eosinophilic asthma in patients 12 years and older, according to the manufacturer release.

The approval of Fasenra (benralizumab, AstraZeneca) stems from the results of a program of studies, which included phase 3 exacerbation trials and a phase 3 oral corticosteroid-sparing trial. The respiratory biologic, which diminishes eosinophils within 24 hours, has not been approved for the treatment of other eosinophilic conditions, or the relief of acute bronchospasms or status asthmaticus.

In the Journals

Recommendations inconsistent in pediatric asthma guidelines

November 8, 2017
Although national and international guidelines for the treatment of pediatric bronchiolitis have many similarities, less agreement is found in guidelines for the
Meeting News

Spirometry underused in primary care

October 31, 2017
BOSTON — Only slightly more than half of all patients presenting to primary care providers with asthma underwent spirometry for diagnosis, according to a presenter…
Meeting News

Omalizumab improves asthma outcomes despite inconsistent adherence

October 30, 2017
BOSTON — Even if children are not fully adherent to treatment, those receiving omalizumab for the management of asthma have a significantly decreased risk of…
More Headlines »